|
|
 Acne (1,500)
Addictions (1,500)
Advice (1,500)
Allergies (1,092)
Alternative Medicine (1,500)
Anti Aging (1,500)
Breakup (1,500)
Cancer (1,499)
Dental Care (1,500)
Disabilities (1,500)
Divorce (1,500)
Elderly Care (1,498)
Goal Setting (1,500)
Hair Loss (1,500)
Health and Safety (1,497)
Hearing (1,500)
Law of Attraction (1,499)
Marriage (1,500)
Medicine (1,497)
Meditation (1,499)
Men's Health (1,500)
Mental Health (1,500)
Motivational (1,500)
Nutrition (1,495)
Personal Injury (1,499)
Plastic Surgeries (1,500)
Pregnancy (1,496)
Psychology (1,500)
Public Speaking (1,500)
Quit Smoking (1,500)
Religion (1,499)
Self Help (1,500)
Skin Care (1,500)
Sleep (1,500)
Stress Management (1,500)
Teenagers (1,492)
Time Management (1,500)
Weddings (1,500)
Wellness (1,500)
Women's Health (1,500)
Women's Issues (1,500)
|
GlobalData, the industry analysis specialist's new report, "Liver Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.
GlobalData analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. However, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
• Annualized global liver cancer market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Tumor Necrosis Factor Alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.
• Analysis of the current and future market competition in the global liver cancer market. Key future market players covered are Bristol-Myers Squibb, Pfizer Inc., F.Hoffmann-La Roche, Bayer Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals and Celsion Corporation.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the liver cancer market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global liver cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global liver cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global liver cancer market landscape? – Identify, understand and capitalize.
|
|
|
